Navigation Links
Trellis(R) Catheter Removes Blood Clots Quickly, Restoring Blood Flow in 771 Deep Vein Thrombosis (DVT) Patients
Date:3/19/2008

Clinical Data Presented at SIR Meeting Indicates New Catheter-based Treatment Could Soon Become the Standard of Care for Treating Acute DVT

WASHINGTON, March 19 /PRNewswire/ -- Registry clinical data presented this week at the Society of Interventional Radiology's 33rd Annual Scientific Meeting shows DVT treatment with the Trellis(R) Peripheral Infusion System from Bacchus Vascular, Inc. (Santa Clara, CA) successfully breaks up the blood clot in most patients in about 20 minutes.

This technique restores blood flow more quickly and safely than current catheter-directed thrombolysis (CDT) techniques. It provides an important adjunct to the standard therapy of anti-coagulation alone, which is intended to prevent future clots but does not break up the existing clot.

Gerard O'Sullivan, MD, Interventional Radiologist from University Hospital in Galway, Ireland, reported the latest outcomes from the manufacturer's registry of clinical results of the Trellis catheter at over 360 hospitals in the U.S. and internationally.

In a total of 827 limbs treated in 771 patients, Grade II and III lysis with restoration of patency in patients with acute clot was achieved in 97% of cases. The vast majority of cases (> 80%) were completed in less than two hours in the single-setting of the interventional suite, and the usage of the Trellis catheter itself was typically around 20 minutes. Although required with CDT procedures, no follow-up monitoring in a costly critical care unit was typically needed with the Trellis catheter treatment.

There were no reported bleeding complications from the Trellis procedure in acute follow up and compared to CDT the dosage of thrombolytic drugs such as t-PA are appreciably reduced with use of the Trellis device.

"The single biggest change in treating DVT patients with the Trellis catheter is our ability to get the clot out and have the patients able to walk away immediately after the procedure," said Dr. O'Sullivan. "Literally, the patient comes into the procedure with difficulty or cannot walk and I can now walk them out of the procedure room at the end of the treatment. These patients are typically back to work in 2-3 days versus the 6-8 weeks with anticoagulation-only treatment."

About Bacchus Vascular

Bacchus Vascular, Inc. is a privately held medical device company dedicated to the treatment of peripheral vascular disease. Dr. Thomas Fogarty, a noted inventor and cardiovascular surgeon, founded the company with the vision of transforming blood clot removal from peripheral blood vessels into a fast, simple, minimally-invasive catheter-based procedure. Thousands of patients suffering from DVT and other occlusive vascular diseases have been treated worldwide to date using the company's Trellis(R) Peripheral Infusion System and other products.

For more information, visit http://www.bacchusvascular.com


'/>"/>
SOURCE Bacchus Vascular, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Study Data Shows VNUS ClosureFAST(TM) Catheter More than 96% Effective
2. YMed, Inc. Successfully Completes First Clinical Cases With Innovative VascuTraK(TM) II PTA Dilatation Catheter
3. Nuvelo Announces Alfimeprase SONOMA-2 Catheter Occlusion Data Presentation Webcast and Conference Call
4. Leading Physicians Present Interim Results from Multi-Center Studies of VNUS ClosureFAST Catheter at VEITHsymposium
5. Rochester Medical Anti-Infection Foley Catheter Demonstrates Effectiveness in Randomized Trial
6. Nuvelo Re-Initiates SONOMA-3 Trial of Alfimeprase in Patients With Catheter Occlusion
7. New Deep Vein Thrombosis (DVT) Registry Data Show Clot Quickly Removed, Blood Flow Restored in Large Patient Registry
8. Gen-Probe Submits U.S. Regulatory Application for Additional Approval of PROCLEIX(R) ULTRIO(R) Blood Screening Assay
9. American Heart Association Journal Report: Reducing Kids Salt Intake May Lower Soft Drink Consumption, Reducing Obesity, High Blood Pressure and Later Health Risks
10. Study Shows: New Blood Test Proven Six Times More Effective For Tuberculosis Control
11. Novel Small Molecule Therapy Shows Benefit for Anemic Patients Via Hydration of Red Blood Cells
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/10/2016)... 2016 Urologix, the market leader for in-office ... Prostatic Hyperplasia (BPH), announces new private ownership and is ... medical device industry veteran of more than 20 years, ... Plymouth, Minn. The ... and Prostiva® RF Therapy, will continue to be broadly ...
(Date:2/10/2016)... 2016 Immune Pharmaceuticals Inc. (NASDAQ: IMNP ... it has filed a patent application directed to the ... --> --> The new ... Ceplene (histamine dihydrochloride) in combination with immune checkpoint inhibitors. ... efficacy of Ceplene and IL-2 therapy in patients with ...
(Date:2/10/2016)... Feb. 10, 2016  Rich Pharmaceuticals, Inc. (OTC Markets: ... 1-for-100 reverse split of its issued and outstanding shares ... on Thursday, February 11, 2016. The Company,s common stock ... number 76303T308 and temporary ticker symbol "RCHAD". After 20 ... the ticker symbol (RCHA).  --> ...
Breaking Medicine Technology:
(Date:2/10/2016)... ... February 10, 2016 , ... Compliancy Group LLC is pleased ... professionals throughout the country. The Guard was specifically designed to handle each element ... training, regulatory updates, and compliance coaching. , In addition to meeting the compliance ...
(Date:2/10/2016)... SAN FRANCISCO, Calif. (PRWEB) , ... February 10, 2016 , ... ... category: Best Water Brand. There were three leading bottled water brand owners that topped ... edge services that enhance connectivity and optimize conversion. The premier brand was Tibet 5100, ...
(Date:2/10/2016)... ... 2016 , ... Ongoing news of the ravages of traumatic brain injury (TBI) ... survey that takes a closer look at cases of TBI being managed by their ... TBI among the aging population, and identifies the challenges associated with their care. , ...
(Date:2/10/2016)... (PRWEB) , ... February 10, 2016 , ... Gout is ... and brings pain that is often severe, with intense swelling and redness. It is ... eight million people, but older adults are the most susceptible, according to the February ...
(Date:2/10/2016)... ... February 10, 2016 , ... AHRA: The Association ... inspirational speaker Jan Fox will serve as keynote speaker at the organization’s 2016 ... with tools to more effectively communicate with their own organizational staff and leadership. ...
Breaking Medicine News(10 mins):